BIO International Convention 2019 Permalink
Jinhan Kim, Standigm CEO is supposed to attend the BIO International Convention 2019.
Event
BIO Asia International Conference 2019 Permalink
Hee Jung Koo and Daehee Han will attend the BIO Asia International Conference 2019.
BIO International Convention 2018 Permalink
Jinhan Kim, Standigm CEO, and Heejung Koo will attend the BIO International Convention 2018.
BIO Asia International Conference 2018 Permalink
Jinhan Kim, Standigm CEO, and Daehee Han will attend the BIO Asia International Conference 2018.
AI Pharma Innovation: Drug Discovery Summit 2018 Permalink
Sang Ok Song, Standigm COO, will speak at the 2018 AI Pharma Innovation Drug Discovery.
Precision Medicine World Conference (PMWC) 2018 Silicon Valley Permalink
Heejung Koo will attend at the PMWC 2018 Silicon Valley and present at the AI company showcase .
BIO-Europe 2017 Permalink
Jinhan Kim, Standigm CEO will speak at the Bio-Europe 2017 on November 7, 2017. Sang Ok Song, Standigm COO will also attend the meeting. Meet them in Berlin.
Artificial Intelligence in Drug Development Congress 2017 Permalink
Jinhan Kim, Standigm CEO, spoke at Artificial Intelligence in Drug Development Congress 2017.
Artificial Intelligence Pharma Innovation Summit 2017 Permalink
Jinhan Kim, Standigm CEO, spoke about “artificial applicable intelligence in drug discovery and repositioning” at AI PHARMA INNOVATION.
Precision Medicine World Conference (PMWC) Silicon Valley Permalink
Jinhan Kim, Standigm CEO, spoke about StandigmAI, the drug repositioning solution, in the Precision Medicine World Conference (PMWC) Silicon Valley.
News
Standigm Collaborates with Excelra to enhance its AI-driven Drug Discovery Process
Hyderabad, India and Seoul, South Korea, Tuesday, 15th September, 2020: Standigm Inc., a company using artificial intelligence (AI) technology for drug dis...
Standigm selects CDD Vault to augment its Drug Discovery AI technology
The hosted informatics platform will facilitate the advancement of Standigm’s collaborative drug discovery projects
SK invests in Standigm for AI-based drug development
HONG KONG – SK Holdings Co. Ltd. invested KRW10 billion (US$8.6 million) in Standigm Inc., an artificial intelligence (AI)-powered biotech company based in S...
Standigm Raises US $11.5 Million in Series B Round Funding to advance its AI-powered drug pipelines toward license-out
Standigm, a company using artificial intelligence (AI) technology for drug discovery and development, announced it has raised 11.5 million dolloar in a Serie...
Standigm is developing incurable disease drugs with AI, in collaboration with big pharma
Standigm is developing drugs for NASH, Parkinson, autism.
Standigm launched new AI driven drug discovery services to the industry
Standigm announced today that it has launched two AI-driven drug discovery services, Expander and Hunter. Expander is a service that new and better indicatio...
Standigm agrees partnership with KIST to discover a new drug for Autism
Standigm and Korea institute of science and technology (KIST) announced a research collaboration to develop a new small molecule medicine for Autism. The dru...
CrystalGenomics, a partner biopharmaceutical company of Standigm, finds first evidence to a new AI-driven drug for cancer.
CrystalGenomics, Inc., Standigm’s partner company, today announced a drug predicted by Standigm’s artificial intelligence technology showed the evidence that...
Standigm announces partnership with Ajou University College of Pharmacy to discover a new small molecule drug for Parkinson’s disease.
Standigm and Ajou university college of pharmacy announced a research collaboration to develop a new small molecule medicine for Parkinson’s disease. Under t...
Standigm and Ajou university medical center sign MOU for an AI-driven clinical drug development
Standigm, Inc. and Ajou university medical center today have signed a Memorandum of Understanding (MOU) for developing drug discovery and improving clinical ...
Standigm and CrystalGenomics announce partnership to discover novel therapeutics in cancer, rheumatoid arthritis and liver related diseases.
Standigm, Inc. and CrystalGenomics, Inc. today agree collaborative partnership with the objective to discover and develop first-in-class drugs in the multipl...
Standigm raises $3 million to advance artificial intelligence for drug discovery
Standigm, Inc. today announced that it has raised $3 million (3.4 billion won) in seed funding from three capital firms: K-Cube Ventures LLC, LB Investment,...
Standigm ranked third in the AstraZeneca-Sanger drug Combination Prediction Dream Challenge
Standigm had participated in the AstraZeneca-Sanger Drug Combination Prediction Dream Challenge hosted by one of the leading pharmaceutical companies, AstraZ...
Press
Report highlights 6 AI startups in healthcare.
Seoul, Korea, South, June 22, 2017 - The advent of artificial intelligence (AI) has global pharmaceutical companies and startups in a race to develop new pro...
CrystalGenomics and Standigm, Agree to Collaborate on Utilizing Artificial Intelligence and Structure-Based Drug Design Technologies in Drug R&D
Seoul, Korea, South, June 01, 2017 –(PR.com)– CrystalGenomics, Inc. (KOSDAQ: 083790) and Standigm, Inc., today announced the collaborative partnership to app...
Global Tech Giants Strengthening Their Competitiveness by Acquiring AI Startups
K Cube Ventures and BonAngels also made the initial investments in Vuno, Solidware, UVify and Standigm as well as Lunit.
Working to improve drug discovery process, Standigm attracts 300 million won from investors
Seoul, Korea, South, February 05, 2016- On February 4th, Standigm, an artificial intelligence and systems biology-based startup, announced that it attracted ...